Table 1 Characteristics of the study population
All (n = 331) | TAV (n = 206) | BAV (n = 125) | P value | |
|---|---|---|---|---|
Age, years | 73.61 ± 7.35 | 74.54 ± 7.33 | 72.09 ± 7.17 | 0.003 |
Male, % (n) | 59.8 (198) | 62.6 (129) | 55.2 (69) | 0.18 |
Body Mass Index, kg/m2 | 22.88 ± 3.60 | 22.71 ± 3.70 | 23.16 ± 3.43 | 0.28 |
NYHA III-IV, % (n) | 62.5 (207) | 60.2 (124) | 66.4 (83) | 0.26 |
LVEF < 50%, % (n) | 37.5 (124) | 36.9 (76) | 38.4 (48) | 0.78 |
STS score, % | 5.09 ± 5.12 | 5.36 ± 5.73 | 4.65 ± 3.91 | 0.23 |
Aortic valve calcium volume, mm3 | 525.30 ± 508.45 | 362.16 ± 371.76 | 730.81 ± 580.64 | < 0.001 |
Comorbidities, % (n) | ||||
Hypertension | 49.5 (164) | 52.4 (108) | 44.8 (56) | 0.18 |
Diabetes | 19.9 (66) | 18.4 (38) | 22.4 (28) | 0.38 |
Coronary artery disease | 22.4 (74) | 22.8 (47) | 21.6 (27) | 0.80 |
Prior myocardial infarction | 1.8 (6) | 2.4 (5) | 0.8 (1) | 0.52 |
Prior stroke | 4.5 (15) | 3.9 (8) | 5.6 (7) | 0.47 |
COPD | 11.8 (39) | 14.6 (30) | 7.2 (9) | 0.04 |
Chronic kidney disease | 6.9 (23) | 6.8 (14) | 7.2 (9) | 0.89 |
Atrial fibrillation | 18.7 (62) | 21.8 (45) | 13.6 (17) | 0.06 |
Prior pacemaker | 3.0 (10) | 3.9 (8) | 1.6 (2) | 0.40 |